Uncategorized Archives - Page 14 of 87 - PsychedelicNewsWire (PNW)

MondayJan 10, 2022 10:26 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelics The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape CYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4). The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled "Psychedelics: More Than Just a Trip" during…

FridayJan 07, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements Both companies intend to pursue rigorous studies to achieve FDA clearance Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping…

ThursdayJan 06, 2022 12:00 pm

Clinical Psychologists Cautiously Evaluating Psychedelic-Backed Mental Health Treatment

A new survey has found that mental health professionals believe that psychedelic substances possess psychological benefits. This was despite concerns about the potential neurocognitive and psychiatric risks linked to using psychedelic treatment. Gabrielle Agin-Liebes, the author of the study, stated that while there was a lot of interest in the potential use of psychedelics in clinical care, there also existed a lot of negative attitudes toward psychedelic therapy. She explained that understanding the extent to which psychedelic treatments would be accepted in the healthcare system would help advance the clinical use of these drugs once they received approval for medical…

ThursdayJan 06, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare…

WednesdayJan 05, 2022 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”) Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six…

TuesdayJan 04, 2022 10:39 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio Once issued, patent may have opportunity to cover a broad range of claims Anxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”) in regard to its patent application connected to its investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders (https://ibn.fm/fpjXm). “The receipt of…

MondayJan 03, 2022 1:20 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Joins Gamechangers LIVE Podcast; Shares Views on the Evolution of the Psychedelics Industry

Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to…

ThursdayDec 30, 2021 3:45 pm

Washington City Approves Measure to Decriminalize Psychedelic Substances

Last week, the city of Port Townsend became the latest city to decriminalize entheogenic fungi and plants through a measure that was unanimously adopted by the city council of Port Townsend. This Washington State city is the latest city to relax its policy on psychedelic substances. Under the approved measure, laws against natural psychedelic plants including ayahuasca, peyote and magic mushrooms, will be the lowest priority for law enforcement in the city. Natural psychedelic substances are sometimes referred to as entheogenic fungi and plants. The initiative also conveys support for the decriminalization of psychedelic drugs at the federal level. In…

WednesdayDec 29, 2021 11:41 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) to Open 2 New Ketamine Infusion Clinics; Co-Founder and CEO Matt Stang Reveals Investor Relations Efforts

Delic Holdings subsidiary, Ketamine Wellness Centers, announced plans to open two new clinics in the coming weeks The clinics, to be located in Salt Lake City, Utah and Reno, Nevada will take KWC’s total clinic count to 14, forming part of the company’s plan to open 13 new ketamine infusion clinics across the country over the next 18 months Following Delic’s keynote ‘Meet Delic’ conference on Nov. 6-7, CEO Matt Stang announced plans to attend the upcoming HC Wainwright Bioconnect Virtual Conference as well as CEM’s 8th annual AlphaNorth Capital Conference in January 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF),…

MondayDec 20, 2021 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022 Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase value for its shareholders There has been a huge misunderstanding of the psychedelic space and the potential that this industry has, specifically regarding the treatment of Post-Traumatic Stress Disorder (“PTSD”) and smoking cessation.…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized